Development and radiolabeling of lipid nanoparticles with [99mTc]Tc-HMPAO: Characterization, stability, cytotoxicity and cell binding studies

Year 2022, Volume: 26 Issue: 1, 88 - 101, 28.06.2025

Evren Atlıhan Gündoğdu , Meliha Ekinci , Emre Özgenç , Emine Selin Demir Derya İlem-özdemir

Abstract

In this study, we aimed to develop new lipid based nanoparticles (LPNs) and radiolabeled LPNs with [99mTc]Tc-HMPAO to investigate its cell binding capacity comparatively with [99mTc]Tc-HMPAO on different cancer cells. According to obtained results, LPNs with zeta potential of -27.4 ± 0.95 mV, particle size of 93.5 ± 1.17 nm, and polydispersity index of 0.35 ± 0.04 were successfully developed. The optimum radiolabeling efficiency was found to be above 90% at 15-min of incubation time. The cell binding capacity of [99mTc]Tc-HMPAO-LPNs was found to be higher than [99mTc]Tc-HMPAO in cancer cell lines. The results demonstrated that [99mTc]Tc-HMPAO-LPNs may be a promising agent for cancer diagnosis alternatively to [99mTc]Tc-HMPAO.

Keywords

Lipid nanoparticles , radiopharmaceuticals , HMPAO , cell binding , cancer diagnosis

References

• [1] Ekinci M, İlem-Özdemir D. Current approaches in nanomedicine. Arch Nano Op Acc J. 2020; 2(3): 183-184. [CrossRef]
• [2] Öztürk AA, Kıyan HT. Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay. Microvasc Res. 2020; 128: 103961. [CrossRef]
• [3] Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol. 2008; 36(1): 43–48. [CrossRef]
• [4] Krishnaiah Y. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab. 2010; 2(2): 28–36. [CrossRef]
• [5] Öztürk AA, Namlı İ, Aygül A. Cefaclor monohydrate-loaded colon-targeted nanoparticles for use in COVID-19 dependent coinfections and intestinal symptoms: Formulation, characterization, release kinetics, and antimicrobial activity. Assay Drug Dev Technol. 2021; 19(3): 156-175. [CrossRef]
• [6] Akbaba H, Karagöz U, Selamet Y, Kantarcı AG. Synthesis and characterization of cationic lipid coated magnetic nanoparticles using multiple emulsions as microreactors. J Magn Magn Mater. 2017; 426; 518-524. [CrossRef]
• [7] İlem-Özdemir D, Gündoğdu E, Ekinci M, Aşıkoğlu M. Nanoparticles: From diagnosis to therapy. Int J Med Nano Res. 2016; 3: 015. [CrossRef]
• [8] Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012; 163(1): 34–45. [CrossRef]
• [9] Ekinci M, İlem-Özdemir D. Radyofarmasötikler ve teranostikler. J Lit Pharm Sci. 2021; 10(1): 119-132. [CrossRef]
• [10] Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B. 1992; 19(5): 539–547. [CrossRef]
• [11] Öztürk AA, Yenilmez E, Arslan R, Şenel B, Yazan Y. Dexketoprofen trometamol loaded solid lipid nanoparticles (SLNs): Formulation, in vitro and in vivo evaluation. J Res Pharm. 2020; 24(1): 82-99. [CrossRef]
• [12] Ekinci M. Master Thesis. Development of Tc-99m labeled drug delivery systems for diagnosis of breast cancer. Department of Radiopharmacy, Institute of Health Science, Ege University, Bornova, Izmir, Turkey, 2015.
• [13] Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014; 461(1–2): 403–410. [CrossRef]
• [14] Schubert S, Delaney JT, Schubert US. Nanoprecipitation and nanoformulation of polymers: From history to powerful possibilities beyond poly(lactic acid). Soft Matter. 2011; 7(5): 1581–1588. [CrossRef]
• [15] Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2015; 111: A3.B.1-A3.B.3. [CrossRef]
• [16] Ekinci M, İlem-Özdemir D, Gündoğdu E, Aşıkoğlu M. Methotrexate loaded chitosan nanoparticles: Preparation, radiolabeling and in vitro evaluation for breast cancer diagnosis. J Drug Deliv Sci Technol. 2015; 30(A): 107-113. [CrossRef]
• [17] İlem-Özdemir D, Ekinci M, Gündoğdu E, Aşıkoğlu M. Estimating binding capability of radiopharmaceuticals by cell culture studies. Int J Med Nano Res. 2016; 3: 014. [CrossRef]
• [18] Akbaba H, Erel-Akbaba G, Kotmakçı M, Başpınar Y. Enhanced cellular uptake and gene silencing activity of survivin-siRNA via ultrasound-mediated nanobubbles in lung cancer cells. Pharm Res. 2020; 37: 165. [CrossRef]
• [19] Ekinci M, İlem-Özdemir D. Nanoteranostikler. Ankara Ecz Fak Derg. 2021; 45(1): 131-155. [CrossRef]
• [20] Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 2005; 45(3-4): 167-173. [CrossRef]
• [21] Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm. 2006; 314(1): 83-89. [CrossRef]
• [22] Gundogdu EA, Demir ES, Ekinci M, Ozgenc E, Ilem Ozdemir D, Senyigit Z, Asikoglu M. The effect of radiolabeled nanostructured lipid carrier systems containing imatinib mesylate on NIH-3T3 and CRL-1739 cells. Drug Deliv. 2020; 27(1): 1695-1703. [CrossRef]
• [23] Hu C, Qian A, Wang Q, Xu F, He Y, Xu J. Industrialization of lipid nanoparticles: From laboratory-scale to large-scale production line. Eur J Pharm Biopharm. 2016; 109: 206-213. [CrossRef]
• [24] Bahari LA, Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull. 2016; 6(2): 143-148. [CrossRef]
• [25] Technetium (99mTc) exametazime injection, European pharmacopoeia online 8.5. Council of Europe. http://online6.edqm.eu/ep805/ (accessed on 8 Sep 2019).
• [26] Huang H, Mei L, Chu T. Synthesis, radiolabeling and biological evaluation of propylene amine oxime complexes containing nitrotriazoles as hypoxia markers. Molecules. 2012; 17(6): 6808-6820. [CrossRef]
• [27] Kim EE. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. J Nucl Med. 2013; 54(2): 324-325. [CrossRef]
• [28] Amin AM, El-Azony KM, Ibrahim IT. Application of 99Mo/99mTc alumina generator in the labeling of metoprolol for diagnostic purposes. J Label Compound Radiopharm. 2009; 52(11): 467–472. [CrossRef]
• [29] Suzuki C, Kosugi M, Magata. Noninvasive quantitation of rat cerebral blood flow using 99mTc-HMPAO assessment of input function with dynamic chest planar imaging. Eur J Nucl Med Mol I. 2018; 8: 21-25. [CrossRef]
• [30] Bonte FJ, Hynan L, Harris TS, White CL. Tc-99m HMPAO brain blood flow imaging in the dementias with histopathologic correlation in 73 patients. Int J Mol Imaging. 2011; 409: 1–3. [CrossRef]
• [31] Blankenberg FG, Kinsman SL, Cohen BH, Goris ML, Spicer KM, Perlman SL. Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Mol Genet Metab. 2012; 107(4): 690–699. [CrossRef]
• [32] Apar Kaya G, Bekis R, Yılmaz O, Ertay T, Durak H. Tc-99m HMPAO uptake in soft tissue infection. Turkish J of Nucl Med. 2005; 14: 130-132.
• [33] Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of manufactured nanoparticles. J Royal Society Interface. 2013; 10(82): 20120939. [CrossRef]
• [34] Park S, Lee SJ, Chung H, Her S, Choi Y, Kim K, Choi K, Kwon IC. Cellular uptake pathway and drug release characteristics of drug‐encapsulated glycol chitosan nanoparticles in live cells. Microscopy ResTechnique. 2010; 73(9): 857–865. [CrossRef]